Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Expert Review of Pharmacoeconomics & Outcomes Research|February 24, 2026
Comparative cost per responder analysis of Ciltacabtagene autoleucel and real-world standard of Care therapy in patients with lenalidomide-refractory multiple myelomaDoris K Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, et al.
Blood Advances|July 23, 2024
Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experienceNilesh M Kalariya, Michelle A T Hildebrandt, Doris K Hansen, et al.
Frontiers in Oncology|November 12, 2025
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary diseaseZiad Abuhelwa, Fnu Amisha, Wenyi Fan, et al.
Journal of Geriatric Oncology|September 18, 2023
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysisOthman Salim Akhtar, Ba Aqeel Sheeba, Farhan Azad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2023
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with MyelomaCiara L Freeman, Reginald Atkins, Indumathy Varadarajan, et al.
Clinical Lung Cancer|January 16, 2026
Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab UseUtsav Joshi, Faustine Ong, Daniel Melzer, et al.
Transplantation and Cellular Therapy|December 20, 2023
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T TherapyOthman S Akhtar, Karnav Modi, Jongphil Kim, et al.
Cancers|October 14, 2023
Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene VicleucelLaura B Oswald, Lisa M Gudenkauf, Xiaoyin Li, et al.
Haematologica|October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experienceHamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
Transplantation and Cellular Therapy|September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy ConsortiumKaren Sweiss, Charlotte Wagner, Eric Anto, et al.
Pageof 4